ライフサイエンスコーパス: modified Rankin Scale

1 the 3-month functional outcome (assessed by modified Rankin Scale).

2 deficits and the patient was rated 0 in mRS (modified Rankin Scale).

3 by functional outcome at hospital discharge (modified Rankin scale).

4 rdiovascular events, and functional outcome (modified Rankin scale).

5 at least one postbaseline measurement of the modified Rankin Scale.

6 Functional ability was rated with the modified Rankin scale.

7 good and poor outcomes as determined by the modified Rankin Scale.

8 ped by functional outcome, determined by the modified Rankin Scale.

9 s, patient and physician reported, including modified Rankin scale.

10 ral Performance Category (CPC) scale and the modified Rankin scale.

11 nd outcome at 3 months was assessed with the modified Rankin Scale.

12 elated with scores on Glasgow Coma Scale and modified Rankin scale.

13 severity of stroke was graded according to a modified Rankin scale.

14 with stroke survivor outcome measured by the modified Rankin Scale.

15 n 75 mm Hg were associated with poor day-180 modified Rankin Scale.

16 unctional outcome was recorded using 3-month modified Rankin Scale.

17 g a functionally independent outcome (90-day modified Rankin Scale 0-2) by 8.3% (P=0.006).

18 ral-Infarction 2b-3), good clinical outcome (modified Rankin Scale 0-2), complications rates, procedu

19 A "good" outcome was defined as modified Rankin Scale 0-3, Barthel Index 70-100, and Gla

20 mortality, (2) favorable functional outcome (modified Rankin Scale = 0-3), and (3) stroke incidence.

21 have good functional outcomes at discharge (modified Rankin Scale, 0-1; 11.3% versus 20.0%; aOR, 0.4

22 Patients who were independent (modified Rankin Scale, 0-3) at discharge or 14 days had

23 Poor outcome was defined as modified Rankin Scale 4-6 at 3 months after SAH.

24 % vs. 3%, p=0.031), death/severe disability (modified Rankin Scale 4-6; 53% vs. 15%, p=0.003) and wor

25 ssociated with reduced risk of poor outcome (modified Rankin Scale, 4-6) at 14 days/discharge and 3 m

26 es showed differences in functional outcome (modified Rankin Scale=4-6: IHC: 29/37 (78.4%) vs non-IHC

27 ctional independence (score of 0 to 2 on the modified Rankin scale, 71% vs. 40%; P=0.01).

28 severe disability or death according to the modified Rankin scale 90 days after the stroke.

29 en readmission and functional outcomes using modified Rankin Scale (a validated functional outcome me

30 severity of disability over the range of the modified Rankin scale (adjusted odds ratio for improveme

31 mortality (7.7% vs 7.3%; p=0.93) and median modified Rankin Scale after 6 months (3 vs 3; p=0.94).

32 The modified Rankin Scale and Barthel Index were more sensit

33 We simultaneously assessed the modified Rankin Scale and health-related quality of life

34 The outcome was assessed using the modified Rankin Scale and school performance in children

35 Readmitted patients had similar modified Rankin Scale and severity of neurologic deficit

36 Relationship between outcome (modified Rankin Scale) and interval times was modeled by

37 trumental activities of daily living (IADL), modified Rankin Scale, and NIH Stroke Score.Compared to

38 ed the overall distribution of scores on the modified Rankin scale, as compared with placebo (P=0.038

39 Outcomes were measured with the modified Rankin Scale at 14 days or discharge, and at 3

40 The primary outcome was the score on the modified Rankin scale at 2 years; this scale measures fu

41 3, representing a favorable outcome, on the modified Rankin scale at 6 months after randomization; s

42 primary outcome measure of the trial is the modified Rankin Scale at 6 months.

43 tcomes were seen for the Hp2-2 patients with modified Rankin scale at 6 wk (P = 0.076) and at 1 y (P

44 e was functional outcome, as measured by the modified Rankin Scale at 90 days and reported as adjuste

45 defined by the distribution of scores on the modified Rankin Scale at 90 days post-randomisation.

46 o for a better distribution of scores on the modified Rankin scale at 90 days was 2.28 (95% confidenc

47 The mean score on the utility-weighted modified Rankin scale at 90 days was 5.5 in the thrombec

48 utcomes included the functional score on the modified Rankin scale at 90 days.

49 bility among the 2 groups as measured by the modified Rankin scale at 90 days.

50 in both groups had a score of 1 to 3 on the modified Rankin scale at admission.

51 iation between SGU, EuroQoL-5 dimension, and modified Rankin Scale at day 90.

52 -PA complication, in-hospital mortality, and modified Rankin Scale at discharge across 3 groups.

53 gest correlation with a score of subacute on modified Rankin scale at discharge.

54 h ESD; n=5891), and stroke survivor outcome (modified Rankin scale at ESD discharge; n=6222).

55 onth mortality was 32.2%, and 70.1% had poor modified Rankin scale at mean follow-up 3.1 +/- 3.5 year

56 of 90-day disability outcomes on the global modified Rankin scale between patients in the magnesium

57 Thirteen patients (50%) improved on the modified Rankin Scale by 1-3 points and four (15%) worse

58 Efficacy was based on modified Rankin scale change at 90 days.

59 which combines dichotomised results from the modified Rankin scale, change in NIHSS score from baseli

60 had shifted down by at least 1 point on the modified Rankin Scale compared to day 7.

61 important determinant, regardless of day or modified Rankin Scale cut point (mean odds ratio 12.51,

62 red seventy-seven (73%) of 378 patients with modified Rankin Scale data were dead or dependent at 1 y

63 Among all patients, mean scores on the modified Rankin scale did not differ between embolectomy

64 ing severity of impairment assessed with the modified Rankin Scale (disabling [modified Rankin Scale

65 t in-hospital and day-90 assessments for the modified Rankin Scale, EuroQoL-5 dimension, and SG.

66 The distribution of outcomes on the modified Rankin scale favored endovascular treatment ove

67 14 (28%) who were not treated; reductions in modified Rankin Scale for children scores were more comm

68 days, as measured according to scores on the modified Rankin scale for disability (range, 0 to 5, wit

69 etween the ALD-401 and placebo groups on the modified Rankin scale for the intent-to-treat population

70 , and 12 months postcardiac arrest using the modified Rankin Scale, Glasgow Outcome Scale, and Barthe

71 res were discharge Glasgow Coma Scale (GCS), modified Rankin Scale, Glasgow Outcome Scale, and hospit

72 mortality and unfavorable outcomes (death or modified Rankin Scale, Glasgow Outcome Scale, or World F

73 middle cerebral artery ischemic stroke with modified Rankin scale >=3.

74 mortality and functional outcomes defined as modified Rankin scale (>=3 at last follow-up was conside

75 Morbidity and mortality (modified Rankin Scale>2) at 1 year occurred in 2/48 (4.2

76 r hyperintensities were associated with poor modified Rankin Scale improvement: adjusted odds ratios

77 hich was defined as a score of 3 to 6 on the modified Rankin scale (in which a score of 0 indicates n

78 The modified Rankin Scale is a sensitive outcome scale in th

79 e was good neurologic function, defined as a modified Rankin Scale less than or equal to 3.

80 the EuroQoL-5 dimension utilities at higher modified Rankin Scale levels.

81 on the rate of excellent outcome at 90 days (modified Rankin Scale </= 2) in each tertile of admissio

82 ed patients aged 18 to 85 years, prehospital modified Rankin Scale </=3, ICH volume < 60ml, Glasgow C

83 an odds ratio 12.51, range [6.01, 22.56] for modified Rankin Scale </=3; mean odds ratio 19.26, range

84 mean odds ratio 62.61, range [2.24, 177] for modified Rankin Scale </=3; mean odds ratio 34.13, range

85 2.35, 95% confidence interval 0.64-5.74 for modified Rankin Scale </=3; odds ratio 2.1, 95% confiden

86 an odds ratio 34.13, range [4.95, 89.93] for modified Rankin Scale </=4).

87 an odds ratio 19.26, range [5.38, 42.26] for modified Rankin Scale </=4).

88 urvival with favorable neurological outcome (modified Rankin scale <3) at hospital discharge.

89 good outcome was determined at two levels by modified Rankin Scale, </=3 as independence and </=4 as

90 ty outcome) and 3-month death or dependency (modified Rankin Scale (mRs) >/=3;efficacy outcome), in p

91 atment and control groups as measured by the modified Rankin Scale (mRS) (with scores ranging from 0

92 econdary outcomes were functional outcome by modified Rankin Scale (mRS) after 3 months (0-6 [symptom

93 nd at days 5 (or discharge), 30, and 90; and modified Rankin Scale (mRS) and Barthel Index (BI) at da

94 assessed the growth of the infarct, and the modified Rankin Scale (mRS) assessed functional outcome

95 ift towards death or dependence rated on the modified Rankin Scale (mRS) at 3 months, and analysed by

96 oint was functional outcome, assessed by the modified Rankin Scale (mRS) at 90 days after stroke.

97 outcome assessed by ordinal analysis of the modified Rankin scale (mRS) at 90 days in the GA and non

98 primary outcome of reduced disability on the modified Rankin Scale (mRS) at 90 days.

99 Clinical outcome was determined by the modified Rankin Scale (mRS) at discharge and in-hospital

100 stigated whether automatic assessment of the modified Rankin Scale (mRS) based on a mobile phone ques

101 Functional outcome was defined by modified Rankin scale (mRS) dichotomized into good (mRS,

102 ieving good functional outcome, defined as a modified Rankin scale (mRS) of 0 to 2 (RR: 1.45; 95% con

103 Day 90 modified Rankin Scale (mRS) outcomes for OTR time interv

104 -cause mortality, death or major disability (modified Rankin Scale (mRS) score >=4) and shift in mRS

105 Degree of disability, measured via the modified Rankin Scale (mRS) score (range 0-6; lower scor

106 were no stroke or TIA, TIA, and stroke with modified Rankin Scale (mRS) score 0 to 1, mRS 2 to 3, an

107 The primary endpoint was the modified Rankin Scale (mRS) score 90 days from onset of

108 lity assessed by overall distribution of the modified Rankin Scale (mRS) score at 90 days, change in

109 ility, activities of daily living (ADLs) and Modified Rankin Scale (MRS) score at admission and disch

110 Main outcome was the modified Rankin Scale (mRS) score for functional outcome

111 The primary outcome was the distribution of modified Rankin Scale (mRS) score obtained by questionna

112 patients achieving independence defined by a modified Rankin Scale (mRS) score of 0-2 at day 90.

113 troke Scale (NIHSS) over 24 hours and 90-day modified Rankin Scale (mRS) score of 0-2.

114 me 90 days after randomisation, defined as a modified Rankin Scale (mRS) score of 0-2.

115 as the proportion of patients who achieved a modified Rankin Scale (mRS) score of 0-3 at 365 days, ad

116 as the proportion of patients who achieved a modified Rankin Scale (mRS) score of 0-4 at 90 days with

117 The primary outcome was a modified Rankin scale (mRS) score of 3 or lower (indicat

118 The primary outcome was 90 day modified Rankin Scale (mRS) score.

119 ween treatment groups with shift analysis of modified Rankin Scale (mRS) score.

120 e; clinical improvement in NIHSS; and 90-day modified Rankin Scale (mRS) score.

121 y clinical end point was 90-day dichotomized modified Rankin Scale (mRS) score.

122 to development of neurological symptoms, and modified Rankin Scale (mRS) score.

123 Ordinal improvement across modified Rankin scale (mRS) scores at 90 days, functiona

124 Modified Rankin Scale (mRS) scores at discharge and othe

125 te end points of death and major disability (modified Rankin scale (mRS) scores of 3-6, 6 and 3-5, re

126 ality, and 3-month functional outcome on the modified Rankin Scale (mRS) using unadjusted and adjuste

127 (TUG), 9-Hole Peg Test (9HPT)), dependency (modified Rankin Scale (mRS)), depression (Beck's Depress

128 tics, stroke severity and type, end-of-trial modified Rankin Scale (mRS), Barthel Index, haematologic

129 luded functional status at 90 days using the modified Rankin Scale (mRS), mortality, and delayed cere

130 follow-up was disability, measured using the modified Rankin Scale (mRS), ranging from 0 (no symptoms

131 ), we examined changes in functional status (modified Rankin Scale (mRS), Rivermead Mobility Index (R

132 ity of life outcomes were measured using the modified Rankin scale (mRS), Telephone Interview for Cog

133 stitutes of Health stroke scale (NIHSS), the modified Rankin scale (mRS), the Barthel index (BI), the

134 ore 90 days after treatment according to the modified Rankin Scale (mRS).

135 t months 4, 8, 12, 18, and 24, by use of the modified Rankin scale (mRS).

136 Outcome was evaluated at 12 months using the modified Rankin Scale (mRS).

137 al Institutes of Health Stroke Scale and the modified Rankin Scale (mRS).

138 e was functional disability evaluated by the modified Rankin Scale ([mRS] score range: 0, no function

139 uding case-fatality rate, favorable outcome (modified Rankin Scale [ mRS modified Rankin Scale ] scor

140 ses of periprocedural death or major stroke (modified Rankin Scale [mRS] > 3) (95% confidence interva

141 Functional outcome was measured by the modified Rankin Scale [mRS] dichotomized as favourable 0

142 e primary outcome was death or poor outcome (modified Rankin scale [MRS] grade 3-5), 6 months after e

143 o hospital discharge with favorable outcome (modified Rankin scale [mRS] score of 0-3).

144 outcome was dependence or death at 3 months (modified Rankin Scale [mRS] score of 3-6).

145 troke Scale score, time from onset, baseline modified Rankin Scale [mRS] score, life expectancy).

146 outcomes were level of disability at day 90 (modified Rankin Scale [mRS] score; range, 0-6); mRS scor

147 SICH); 3-month functional independence (FI) (modified Rankin Scale [mRS] scores 0-2) represented the

148 2b-3), ambulatory status, global disability (modified Rankin Scale [mRS]) and destination at discharg

149 able functional outcome (score of 0-1 on the modified Rankin Scale [mRS]) at 90 days indicating no di

150 er of relapses), outcomes (measured with the modified Rankin scale [mRS]), and phenotypes associated

151 T with functional outcome (measured with the modified Rankin Scale [mRS]), by means of ordinal logist

152 functional outcomes (Barthel index [BI] and modified Rankin scale [mRS]), the incidence of intracere

153 sed the odds of being alive and independent (modified Rankin Scale, mRS 0-2) at final follow-up (1611

154 ples from 45 patients (25 with good outcome [modified Rankin Scale, mRS 0-2], ten with poor outcome [

155 Favorable outcome (defined as modified Rankin scale of <or=2) and death at 1-month was

156 proportion (6.8% [4.0% to 9.5%]) achieving a modified Rankin Scale of 0 or 1 (excellent outcome) exce

157 e percentage of patients with a score on the modified Rankin scale of 0 to 2, signifying an absence o

158 Favorable outcome was defined as a modified Rankin Scale of 0 to 3 at first follow-up.

159 ity of survival to hospital discharge with a modified Rankin scale of 0 to 3 declines rapidly with ea

160 ospital discharge was 11%, but only 6% had a modified Rankin scale of 0 to 3.

161 death or dependence at 1 year (defined by a modified Rankin scale of 3-6).

162 se were considered neurologically recovered (modified Rankin scale of zero), while 36 patients were n

163 schaemic or haemorrhagic; assessed using the modified Rankin Scale) or TIA within 90 days, as assesse

164 available at all timepoints improved to good modified Rankin Scale outcome and none worsened to poor

165 days over the entire range of scores on the modified Rankin scale (P<0.001).

166 es (as indicated by a score of 0 to 1 on the modified Rankin scale) (P=0.20).

167 ome was assessed at 3 and 12 months with the modified Rankin Scale; quality of life (QOL), with the S

168 The primary outcome was the score on the modified Rankin scale (range, 0 [no symptoms] to 6 [deat

169 ity at 90 days, as measured by scores on the modified Rankin scale (range, 0 to 6, with higher scores

170 al disability at 90 days, as measured on the modified Rankin scale (ranging from 0 [no symptoms] to 6

171 We assessed outcomes using the 90-day modified Rankin scale, ranging from 0 (no symptoms) to 6

172 Those cohorts with modified Rankin Scale recorded at time points other than

173 me was death or major disability at 90 days (modified Rankin Scale score >/=3) and the secondary outc

174 a combination of death and major disability (modified Rankin Scale score >/=3) at 3 months.

175 or improved outcome (relative risk of 90-day modified Rankin Scale score >/=4, 1.24; 95% CI, 0.53-2.9

176 e < or =2 points] to disability at 6 months [modified Rankin scale score >2 points]) or death, compar

177 d with the modified Rankin Scale (disabling [modified Rankin Scale score >3] versus nondisabling [mod

178 progression from no disability before event [modified Rankin scale score < or =2 points] to disabilit

179 = .01), and had better outcome (defined by a modified Rankin Scale score </= 2 at last visit; 84% vs

180 ollow-up of 7.4 years, 82% of patients had a modified Rankin Scale score </= 2.

181 outcome was 3-month functional independence (modified Rankin scale score </=2).

182 38%) achieved moderate disability or better (modified Rankin Scale score </=3) by 1 year after stroke

183 o 2.1, 95% confidence interval 0.81-4.24 for modified Rankin Scale score </=4).

184 Rankin Scale score >3] versus nondisabling [modified Rankin Scale score <=3]) over time, and associa

185 The primary outcome was a favourable modified Rankin Scale score (0-2) at day 90 in all treat

186 Modified Rankin Scale score (0-2) at day 90 occurred in

187 with a favorable outcome based on the 90-day modified Rankin Scale score (a global stroke disability

188 The primary outcome was reported using the modified Rankin Scale score (disability range, 0 [no sym

189 me was good functional outcome, defined as a modified Rankin Scale score (mRS) of 3 or less at 180 da

190 Secondary outcomes included the modified Rankin scale score (on a scale from 0 to 6, wit

191 mortality, discharge ambulatory status, and modified Rankin Scale score (range, 0 [no symptoms] to 6

192 m PSC door to CSC groin puncture, and 90-day modified Rankin Scale score (range, 0-6; scores of 0-2 i

193 Measures: The primary outcome was the 90-day modified Rankin Scale score (range, 0-6; scores of 0-2 i

194 h functional outcome significantly improved (modified Rankin Scale score 0-1 in 375 [40%] of 944 pati

195 ent outcomes when treated with tenecteplase (modified Rankin scale score 0-1: odds ratio, 1.77; 95% c

196 0.001) and better late independent recovery (modified Rankin scale score 0-1: odds ratio, 2.33; 95% c

197 Favorable clinical outcome was defined as modified Rankin scale score 0-2 at 3 months after stroke

198 al hemorrhage (sICH), and favorable outcome (modified Rankin Scale score 0-2) at 3 months.

199 ith neurosurgical clipping were independent (modified Rankin scale score 0-2; OR 1.25; 95% CI 0.92-1.

200 f Health Stroke Scale [NIHSS] score >/=6 and modified Rankin Scale score 2-4) 6-60 months after ischa

201 002]) and to advanced functional disability (modified Rankin Scale score 3 to 6 vs. 0 to 2: 135.1 pmo

202 We assessed functional outcome (modified Rankin scale score 3-6) and mortality at 90 day

203 2.45x10(-5)) and poorer functional outcomes (modified Rankin scale score 3-6; 1.52, 1.25-1.85; p=1.74

204 more severe disability on discharge (median modified Rankin Scale score 4 vs 3, p<0.0001) and inpati

205 ent (common OR [cOR] for 1-point decrease in modified Rankin Scale score = 1.52, 95% CI = 1.18-1.97),

206 Independent predictors of poor modified Rankin Scale score at 30 days were percent of i

207 The primary outcome was improvement in the modified Rankin Scale score at 90 days in patients enrol

208 roup, the adjusted cOR for an improvement in modified Rankin Scale score at 90 days in the interventi

209 Primary outcome was the modified Rankin Scale score at 90 days.

210 The primary outcome was the modified Rankin scale score at 90 days; this categorical

211 After ICH, the modified Rankin scale score at discharge was >/=4 in 55.

212 sociated with any significant changes in the modified Rankin scale score distribution (MAC: OR, 1.52;

213 sitivity, 30% [95% CI: 18%, 45%]) or 6-month modified Rankin scale score greater than 3 (specificity,

214 ncy at 2 weeks, with dependency defined as a modified Rankin scale score greater than 3 points.

215 ma expansion rate was associated with poorer modified Rankin Scale score in an ordinal shift analysis

216 We assessed dependency as self-reported modified Rankin scale score obtained through yearly ques

217 rest were mortality and poor 90-day outcome (modified Rankin Scale score of >/=3).

218 Frequency of good outcome (defined as a modified Rankin Scale score of </= 2) and mortality at 6

219 harge with favourable neurological function (modified Rankin scale score of </=3).

220 Scale score of >or=8 points at 30 days or a modified Rankin scale score of 0 or 1 at 30 days) in pat

221 tients who had an excellent outcome (i.e., a modified Rankin scale score of 0 or 1).

222 was favourable outcome, defined as either a modified Rankin scale score of 0 or 1, or an NIHSS score

223 Favorable outcome was defined as a modified Rankin Scale score of 0 to 1 at 3 months.

224 Stroke Scale and a favorable odds ratio of a modified Rankin scale score of 0 to 1 versus 2 to 6 comp

225 Good (moderate) outcome was defined as a modified Rankin Scale score of 0 to 2 (0-3) assessed aft

226 No patients had a modified Rankin scale score of 0 to 2 (survival with no

227 es, rates of acceptable outcome defined as a modified Rankin Scale score of 0 to 3 at hospital discha

228 Primary efficacy end point was a modified Rankin Scale score of 0-1 at 90 days, adjusted

229 to model good clinical outcome (defined as a modified Rankin Scale score of 0-2 at 3 months) as a fun

230 ood clinical outcome, which was defined as a modified Rankin Scale score of 0-2 at day 90.

231 Good outcome was defined as a modified Rankin Scale score of 0-2 at follow-up.

232 vourable functional outcome was defined as a modified Rankin Scale score of 0-2 or a Glasgow Outcome

233 Functional independence (modified Rankin Scale score of 0-2) and mortality at 3 m

234 essful reperfusion, functional independence (modified Rankin Scale score of 0-2) and mortality at 90

235 ed by the percentage of patients achieving a modified Rankin Scale score of 0-2, analysed by intent t

236 t 6 months after ICU admission, defined by a modified Rankin Scale score of 0-2.

237 The primary outcome measure was a modified Rankin scale score of 2 or less (indicating fun

238 baseline NIHSS score of 10 or higher, with a modified Rankin Scale score of 2 or less achieved in onl

239 nt was good functional outcome, defined as a modified Rankin scale score of 2 or less at day 90.

240 MCA-M2 occlusions, respectively, achieved a modified Rankin Scale score of 2 or less, and 6 (23.1%),

241 Poor 3-month outcome was defined as modified Rankin Scale score of 3 to 6.

242 Poor clinical outcome (defined as modified Rankin Scale score of 3-6) was reported in 29 o

243 ad or disabled at discharge (77% vs 65% with modified Rankin Scale score of 3-6; AOR = 1.64; 95% CI,

244 unfavorable outcome was defined as a 90-day modified Rankin Scale score of 4 or greater (range, 0-6)

245 d or were severely disabled (as defined by a modified Rankin Scale score of 4 to 6), as compared with

246 hemia-related infarction and poor outcome (a modified Rankin Scale score of 4, 5, or death at 3 mo).

247 performed to predict grave outcomes (3-month modified Rankin Scale score of 5-6).

248 Median (interquartile range) modified Rankin Scale score was 2 (1-3) at discharge and

249 The modified Rankin Scale score was analyzed by ordinal logi

250 no history of stroke and prestroke handicap (modified Rankin Scale score, < 2).

251 al : 6.7%, 19.7%), a favorable outcome ( mRS modified Rankin Scale score, </=2) was seen in 42.5% of

252 The rate of functional independence (modified Rankin scale score, 0 to 2) was higher in the i

253 o treat, 43) and better functional outcomes (modified Rankin Scale score, 0-1) at discharge (24.1% vs

254 Scale score, 0-2), 90-day excellent outcome (modified Rankin Scale score, 0-1), and occurrence of any

255 outcomes included 90-day favorable outcome (modified Rankin Scale score, 0-2), 90-day excellent outc

256 Factors associated with favorable (modified Rankin Scale score, 0-3) vs unfavorable functio

257 on the occurrence of an unfavorable outcome (modified Rankin Scale score, 3-6) (odds ratio, 1.20; 95%

258 tors associated with an unfavorable outcome (modified Rankin Scale score, 3-6), any new intraventricu

259 43) of survivors had an unfavorable outcome (modified Rankin Scale score, 3-6).

260 associated with death or severe disability (modified Rankin Scale score, 4-6) at 3 months in a multi

261 Part II score, the UPDRS Part III score, the modified Rankin Scale score, level of education, and tre

262 edema expansion rate at 24 hours and 90-day modified Rankin Scale score.

263 in response to external stimuli) and 6-month modified Rankin scale score.

264 uded neurological outcome assessed using the modified Rankin Scale (score 0 [no symptoms] through 6 [

265 vorable outcome (modified Rankin Scale [ mRS modified Rankin Scale ] score, </=2), and rates of SICH

266 Functional outcomes were recorded with modified Rankin Scale (scored from 0 [no symptoms] to 6

267 since first antibody detection), the median modified Rankin scale scores (excluding the four deaths)

268 s and death at 7 and 90 days; good recovery (modified Rankin Scale scores 0-2 at 90 days) and sICH.

269 re unfavourable functional outcome (primary, modified Rankin scale scores 3-6 or 2-6), death, interme

270 ithrombotic use and (1) death or dependency (modified Rankin scale scores 3-6) were analysed using lo

271 rs and either death, or death or dependence (modified Rankin Scale scores = 4-6) 1 year after first-e

272 The distribution of modified Rankin scale scores at 1 year, 5 years, or fina

273 ologic deficit at 14 days but higher (worse) modified Rankin Scale scores at 3 months (median [interq

274 he secondary outcome was an ordinal shift in modified Rankin Scale scores at 90 days, assessed by inv

275 f death and major disability were defined by modified Rankin Scale scores at 90 days.

276 tus showed that the distributions of 3-month modified Rankin Scale scores differed across white matte

277 Good outcomes, as defined by 90-day modified Rankin Scale scores of 0 to 2, were analyzed by

278 %) of 143 patients in the placebo group, had modified Rankin Scale scores of 0-2 (adjusted absolute r

279 Impact on 30- and 180-days modified Rankin Scale scores was assessed, and receiver

280 Modified Rankin scale scores were assigned based on tele

281 ional status at 90 days measured by shift in modified Rankin scale scores, analysed with unadjusted o

282 ries reports sequential seizure frequencies, modified Rankin Scale scores, and VGKC-complex antibody

283 tional Institutes of Health Stroke Scale and modified Rankin scale scores.

284 t quintile was associated with worse 3-month modified Rankin Scale scores: adjusted odds ratio for th

285 independently associated with worse 3-month modified Rankin Scale scores; adjusted odds ratios (95%

286 versus the first quintile) had worse 3-month modified Rankin Scale scores; adjusted odds ratios were

287 al status was defined by 5 outcome measures: Modified Rankin Scale, Symbol Digit Modalities Test, PDQ

288 tervention would lead to lower scores on the modified Rankin scale than would control care (shift ana

289 In the analysis using the modified Rankin scale, the comparable rate was 52% in bo

290 In ordinal analysis of the modified Rankin Scale, the median (IQR) value was 1 (1-6

291 the primary analysis of scores on the 90-day modified Rankin scale, there was no interaction between

292 The modified Rankin Scale was prospectively determined at ho

293 Day-90 SGU and modified Rankin Scale were significantly correlated; how

294 an 60 mm Hg were associated with poor day-30 modified Rankin Scale, whereas cerebral perfusion pressu

295 score for disability on the utility-weighted modified Rankin scale (which ranges from 0 [death] to 10

296 ability (defined by a score of 0 to 4 on the modified Rankin scale, which ranges from 0 [no symptoms]

297 ctory function (i.e., a score of </=3 on the modified Rankin scale, which ranges from 0 to 6, with hi

298 l independence (a score of 0, 1, or 2 on the modified Rankin scale, which ranges from 0 to 6, with hi

299 lity at 90 days, as assessed by means of the modified Rankin scale (with scores ranging from 0 [no sy

300 dependence (defined as a score of 0-2 on the modified Rankin Scale, with 0 indicating no disability a